Valuation : Rapport Therapeutics, Inc.

Market Cap 2.2B 1.89B 1.78B 1.62B 3.04B 207B 3.05B 21.01B 8.15B 106B 8.25B 8.07B 343B P/E 2026 *
-11.3x
P/E 2027 * -9.34x
Enterprise Value 1.87B 1.61B 1.51B 1.38B 2.58B 176B 2.59B 17.86B 6.93B 90.43B 7.01B 6.86B 291B EV / Sales 2026 *
93.3x
EV / Sales 2027 * -
Free-Float
96.08%
Yield 2026 *
-
Yield 2027 * -
1 day-3.95%
1 week-6.15%
Current month-5.96%
1 month+7.85%
3 months+26.79%
6 months+54.37%
Current year+50.86%
1 week 45.52
Extreme 45.52
50.34
1 month 44.91
Extreme 44.91
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 22.06
Extreme 22.06
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 01/01/2023
Chief Executive Officer 48 01/02/2023
Director of Finance/CFO 58 01/11/2023
Director TitleAgeSince
Director/Board Member 61 23/08/2023
Director/Board Member 48 01/03/2023
Director/Board Member 54 01/02/2022
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Sell

Executive/Senior Manager

-37,000 0.0774%
25/08/26 Sell

Chief Executive Officer

-18,921 0.0396%
19/08/26 Sell

Executive/Senior Manager

-404 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-3.95%-6.15%+218.73% - 2.2B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -1.22%-0.13%+90.13%+109.63% 27.72B
Weighted average by Cap. -1.06%+0.06%+90.51%+127.93%

Financials

2026 *2027 *
Net sales 20M 17.21M 16.19M 14.79M 27.67M 1.89B 27.75M 191M 74.25M 969M 75.1M 73.46M 3.12B -
Net income -194M -167M -157M -144M -269M -18.33B -269M -1.86B -721M -9.4B -729M -713M -30.29B -252M -217M -204M -187M -349M -23.83B -350M -2.41B -937M -12.23B -948M -927M -39.39B
Net Debt -329M -283M -266M -243M -455M -31.07B -457M -3.15B -1.22B -15.94B -1.24B -1.21B -51.36B -477M -410M -386M -353M -660M -45.01B -661M -4.56B -1.77B -23.09B -1.79B -1.75B -74.39B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
04/09/26 $45.77 -3.95% 279,884
03/09/26 $47.65 -2.14% 276,962
02/09/26 $48.69 +0.27% 294,754
01/09/26 $48.56 -0.23% 148,596
31/08/26 $48.67 -0.21% 221,024
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
45.77USD
Average target price
62.05USD
Spread / Average Target
+35.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock